Global GLP-1 Analogues Market Size & Trends Report Segmented by Product (Ozempic, Mounjaro, Wegovy, Rybelsus, Saxenda), Route of Administration (Subcutaneous, Oral), Application (Diabetes, Obesity), End-user Analysis & Regional Forecast to 2031
The global GLP-1 analogues market size is expected to grow at a CAGR of 14% during the forecast period. The rising prevalence of type 2 diabetes and obesity, increasing adoption for chronic weight management among non-diabetic populations, expansion of pharmaceutical R&D pipelines, and growing demand in emerging markets with high metabolic disease burden are key drivers of market growth. However, strict regulatory requirements and limited reimbursement policies remain a major restraint for the GLP-1 analogues market. To learn more about the research report, download a sample report.
Glucagon-like peptide-1 (GLP-1) analogues are medications primarily used in the treatment of type 2 diabetes and obesity, which mimic the action of the natural hormone GLP-1, which is necessary for regulating glucose levels in the body. GLP-1 stimulates insulin secretion, suppresses glucagon release, delays the emptying of the stomach, and increases satiety. This hormone is released post-meals by intestinal L-cells. GLP-1 analogues target several pathophysiological variables linked to type 2 diabetes primarily by enhancing the body's natural ability to regulate blood sugar levels and thereby lowering the risk of hypoglycemia. Additionally, even in non-diabetic populations, their ability to decrease hunger has created opportunities for their application in weight management.
To learn more about this report, download the PDF brochure
The dual burden of type 2 diabetes and obesity drives the demand for GLP-1 analogues
A key factor driving the demand for GLP-1 analogues is the surge in the number of people with type 2 diabetes and obesity due to growing adoption of sedentary lifestyles, poor food choices, and rapid urbanization. According to the International Diabetes Federation (IDF), 589 million adults (20-79 years) are living with diabetes, and in 2024, statistics show that diabetes alone caused 3.4 million deaths. The World Obesity Federation’s 2025 Atlas projects that over 1 billion people will be living with obesity by 2030.
GLP-1 analogues are particularly effective as they address weight loss and glycemic management simultaneously, so they become essential in managing the dual burden of diabetes and obesity. Growing awareness of the long-term complications of uncontrolled diabetes, like neuropathy and cardiovascular disease, is also a critical aspect which further drives the demand for GLP-1 analogues. Additionally, growing awareness of early diagnosis, preventive care, and lifestyle modification programs are being actively promoted by public health groups and health authorities is indirectly increasing demand for GLP-1–based therapies.
To learn more about this report, download the PDF brochure
GLP-1 analogues for weight management in non-diabetic populations gain traction
One of the notable trends seen in the GLP-1 analogues market is the growing adoption of these therapies for obesity treatment in non-diabetic patients. GLP-1 analogues like semaglutide and liraglutide, which were primarily used for glycemic control, are now being widely prescribed, particularly for the management of chronic weight management. Obesity is increasingly associated with many severe disorders, like cardiovascular disorders, sleep apnea, and certain cancers; hence, healthcare professionals are looking for therapies that are effective for long-term weight management.
The global shift toward preventive wellness, along with significant sustained weight loss by GLP-1 analogues, has further strengthened their role in metabolic health. As a result, GLP-1 analogues are now positioned not only as diabetes drugs but also as cornerstone therapies in modern obesity care, drawing in new patient segments. Moreover, pharma companies are accelerating R&D to evaluate their impact in other sectors. For instance,
- In July 2024, the MHRA approved Semaglutide, a GLP-1 receptor agonist, to reduce the risk of major cardiovascular events in obese or overweight people, underscoring its expanding benefits beyond glycemic control
- In December 2023, Eli Lilly and Company launched Zepbound (tirzepatide), the first dual GIP/GLP-1 receptor agonist for chronic weight management in adults with obesity or other weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease
Together, such developments are reshaping the role of GLP-1 analogues from single-purpose treatments to comprehensive metabolic health solutions.
Competitive Landscape Analysis
The global GLP-1 analogues market comprises of several well-established and emerging players, including Eli Lilly and Company; Novo Nordisk A/S; Pfizer Inc.; AstraZeneca PLC; Sanofi S.A.; Sun Pharmaceutical Industries Limited; Boehringer Ingelheim International GmbH; PegBio Co., Ltd.; Innovent Biologics, Inc.; and Amgen Inc., among others. Key strategies adopted by these players include the development of advanced therapies, mergers and acquisitions, and investment in R&D to enhance diabetic and chronic weight management solutions and meet growing global demand.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2025 |
| Historical Data | 2024 - 2025 |
| Forecast Period | 2026 – 2031 |
| Growth Rate | 14% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Product, Route of Administration, Application, and End-user |
| Regional Scope |
|
| Key Companies Mapped | Eli Lilly and Company; Novo Nordisk A/S; Pfizer Inc.; AstraZeneca PLC; Sanofi S.A.; Sun Pharmaceutical Industries Limited; Boehringer Ingelheim International GmbH; PegBio Co., Ltd.; Innovent Biologics, Inc.; and Amgen Inc.; among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global GLP-1 Analogues Market Segmentation
This report by Medi-Tech Insights provides the size of the global GLP-1 analogues market at the regional- and country-level from 2024 to 2031. The report further segments the market based on product, route of administration, application, and end-user.
Market Size & Forecast (2024-2031), By Product, USD Million
- Ozempic
- Trulicity
- Mounjaro
- Wegovy
- Rybelsus
- Saxenda
- Others
Market Size & Forecast (2024-2031), By Route of Administration, USD Million
- Subcutaneous
- Oral
Market Size & Forecast (2024-2031), By Application, USD Million
- Diabetes
- Obesity
- Others
Market Size & Forecast (2024-2031), By End-user, USD Million
- Hospitals
- Specialty Clinics
- Home-care Settings
- Others
Market Size & Forecast (2024-2031), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the GLP-1 analogues market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the GLP-1 analogues market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2026-2027)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- GLP-1 Analogues Market Snapshot (2026-2031)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Rising prevalence of type 2 diabetes and obesity
- Expanding pharmaceutical R&D pipelines and innovative GLP-1 combinations
- Increasing adoption for chronic weight management among non-diabetic populations
- Growing healthcare spending on chronic disease management
- Rising awareness of metabolic health and preventive care
- Restraints
- High therapy cost and complex manufacturing requirements
- Strict regulatory requirements
- Limited reimbursement policy
- Opportunities
- Development of dual or multi-agonist therapies
- Expansion into adolescent obesity and pediatric diabetes treatment
- Adoption of oral GLP-1 analogues improving patient convenience
- Rising demand in emerging markets with high metabolic disease burden
- Key Market Trends
- Growing use of GLP-1 treatments for cardiovascular and renal risk reduction
- Increased integration of digital tools for adherence and remote monitoring
- Unmet Market Needs
- Industry Speaks
- Drivers
- Market Dynamics
- Global GLP-1 Analogues Market Size & Forecast (2024-2031), By Product, USD Million
- Introduction
- Ozempic
- Trulicity
- Mounjaro
- Wegovy
- Rybelsus
- Saxenda
- Others
- Global GLP-1 Analogues Market Size & Forecast (2024-2031), By Route of Administration, USD Million
- Introduction
- Subcutaneous
- Oral
- Global GLP-1 Analogues Market Size & Forecast (2024-2031), By Application, USD Million
- Introduction
- Diabetes
- Obesity
- Others
- Global GLP-1 Analogues Market Size & Forecast (2024-2031), By End-user, USD Million
- Introduction
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
- Global GLP-1 Analogues Market Size & Forecast (2024-2031), By Region, USD Million
- Introduction
- North America GLP-1 Analogues Market Size & Forecast (2024-2031), By Country, USD Million
- US
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Canada
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- US
- Europe GLP-1 Analogues Market Size & Forecast (2024-2031), By Country, USD Million
- UK
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Germany
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- France
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Italy
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Spain
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Rest of Europe
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- UK
- Asia Pacific (APAC) GLP-1 Analogues Market Size & Forecast (2024-2031), By Country, USD Million
- China
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Japan
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- India
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- China
- Latin America (LATAM) GLP-1 Analogues Market Size & Forecast (2024-2031), USD Million
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Middle East & Africa (MEA) GLP-1 Analogues Market Size & Forecast (2024-2031), USD Million
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Route of Administration (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2025)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2023-2025)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- Eli Lilly and Company
- Novo Nordisk A/S
- Inc
- AstraZeneca PLC
- Sanofi S.A.
- Sun Pharmaceutical Industries Limited
- Boehringer Ingelheim International GmbH
- PegBio Co., Ltd.
- Innovent Biologics, Inc.
- Amgen Inc.
- Other Prominent Players
Note: *Indicative list
**For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Hospitals, Biopharmaceutical & Biotechnology Companies, and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
Features of the Report
- Comprehensive Market Coverage
- Market Size and Forecast
- Geographic & Segment Deep Dives
- Strategic Insights & Competitive Landscape
- Timely & Updated Data
- Growth Indicators & Future Outlook
- Quick Turnaround on Queries
- Analyst Support
- Report Customization Available
- Reports in PDF & Excel
